ACADIA Pharmaceuticals Inc. vs Bank of Nova Scotia — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.84 (market cap $5.07B), while Bank of Nova Scotia trades at $89.03 (market cap $108.32B). The key difference: Bank of Nova Scotia is far larger — about 21.4× ACADIA Pharmaceuticals Inc.'s market cap, and Bank of Nova Scotia pays a 3.64% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BNS | |
|---|---|---|
Market Cap | $5.07B | $108.32B |
Sector | Health | Financials |
52-Week High | $29.41 | $90.29 |
52-Week Low | $20.06 | $56.41 |
Enterprise Value | $4.19B | — |
Dividend Yield | — | 3.64% |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →